Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy in Treating Women With Breast Cancer

Study:

Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for breast cancer.

Purpose:

Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating women with breast cancer who have undergone surgery to remove the tumor.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Breast Cancer Drug: cyclophosphamide
Drug: docetaxel
Drug: doxorubicin hydrochloride
Phase 3

Verified by Eastern Cooperative Oncology Group January, 2010

Sponsored by: Eastern Cooperative Oncology Group
Information provided by: Eastern Cooperative Oncology Group
ClinicalTrials.gov identifier: NCT00003519

Study Type: Interventional

Study Design: Allocation: Randomized, Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

Lori J. Goldstein, MD., Study Chair
Silvana Martino, DO., Study Chair
Edith A. Perez, MD., Study Chair
Larry Norton, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site